Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CLARITY MEDICAL GROUP HOLDING LIMITED
清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2026

FINANCIAL HIGHLIGHT

	For the year ended 31 March		
	2026	2025	**Change**
	HK$'000	*HK$'000*	**%**
Revenue	**177,820**	180,592	**(1.5)%**
Loss for the year	**(46,412)**	(34,289)	**(35.4)%**
Adjusted EBITDA[1&2]	**(10,024)**	(6,149)	**(63.0)%**

Notes:

(1) Adjusted EBITDA is derived from EBITDA (Earnings before interest, taxes and depreciation of plant and equipment) by excluding one-off impairment losses on plant and equipment and right-of-use assets, other income and gains/(losses), net, as well as non-recurring expenditures, mainly consisting of non-recurring professional fees, including legal and advisory fees related to the allegations and issues disclosed in the announcements of the Company dated 30 May 2025 and 30 June 2025.

(2) This non-GAAP financial data is a supplemental financial measure that is not required by, or presented in accordance with, HKFRSs and is therefore referred to as a "non-GAAP" financial measure.

The board (the "**Board**") of directors (the "**Directors**") of Clarity Medical Group Holding Limited (the "**Company**") announces the annual consolidated results of the Company and its subsidiaries (collectively, the "**Group**") for the year ended 31 March 2026 ("**FY2026**"), together with the comparative figures for the year ended 31 March 2025 ("**FY2025**"), as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 March 2026

		Year ended 31 March	
		2026	2025
	Notes	***HK$'000***	*HK$'000*
Revenue	*3*	**177,820**	180,592
Other income and gains/(losses), net	*4*	**2,058**	2,280
Inventories used		**(35,391)**	(37,996)
Consultancy fee		**(62,004)**	(64,343)
Employee benefit expenses		**(52,484)**	(50,213)
Depreciation of plant and equipment		**(9,835)**	(10,636)
Depreciation of right-of-use assets		**(12,373)**	(12,394)
Impairment loss on plant and equipment		**(83)**	(4,388)
Impairment loss on other receivables		**–**	(1,838)
Other expenses	*5*	**(54,992)**	(36,938)
Operating loss		**(47,284)**	(35,874)
Finance costs	*6*	**(788)**	(1,038)
Loss before income tax		**(48,072)**	(36,912)
Income tax	*7*	**1,660**	2,623
Loss for the year		**(46,412)**	(34,289)
Other comprehensive income (expense)			
Other comprehensive income (expense) that may be reclassified subsequently to profit or loss:			
Exchange differences on translation of foreign operations		**363**	(116)
Total comprehensive expense for the year attributable to owners of the Company		**(46,049)**	(34,405)
Loss per share attributable to owners of the Company (expressed in HK cents per share)			
– Basic and diluted	*8*	**(8.6)**	(6.5)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 March 2026

		As at 31 March	
		2026	2025
	Notes	***HK$'000***	*HK$'000*
Non-current assets			
Plant and equipment		**21,236**	30,707
Right-of-use assets		**28,406**	8,682
Deposits	*11*	**3,099**	3,300
Financial assets at fair value through profit or loss		**4,630**	4,375
Deferred tax assets		**10,717**	9,057
Total non-current assets		**68,088**	56,121
Current assets			
Inventories		**2,186**	2,517
Trade receivables	*10*	**5,325**	4,787
Deposits, prepayments and other receivables	*11*	**2,390**	3,706
Cash and cash equivalents		**92,019**	132,573
Total current assets		**101,920**	143,583
Current liabilities			
Trade payables	*12*	**6,610**	5,627
Accruals and other payables		**12,780**	15,948
Provisions		**–**	5,734
Lease liabilities		**11,855**	7,688
Total current liabilities		**31,245**	34,997
Net current assets		**70,675**	108,586
Total assets less current liabilities		**138,763**	164,707
Non-current liabilities			
Provisions		**4,685**	1,193
Lease liabilities		**16,637**	2,220
Total non-current liabilities		**21,322**	3,413
Net assets		**117,441**	161,294

	As at 31 March	
	2026	2025
	HK$'000	*HK$'000*
Capital and reserves		
Share capital	**5,363**	5,289
Share premium	**312,751**	306,415
Reserves	**(200,673)**	(150,410)
Total equity	**117,441**	161,294

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 March 2026

1 GENERAL INFORMATION

Clarity Medical Group Holding Limited (the "**Company**") was incorporated in the Cayman Islands on 19 February 2019 as an exempted company with limited liability under the Companies Act of the Cayman Islands. The address of the Company's registered office is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands.

The Company is an investment holding company. The Company and its subsidiaries (collectively referred to as the "**Group**") are principally engaged in the provision of ophthalmic services in Hong Kong. The principal place of business of the Group is 20/F, Ginza Plaza, 2A Sai Yeung Choi Street South, Mongkok, Kowloon, Hong Kong.

2 ACCOUNTING POLICIES

2.1 Basis of preparation

The consolidated financial information has been prepared in accordance with HKFRS Accounting Standards (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("**HKASs**") and Interpretations) as issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**") and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention except for financial assets at fair value through profit or loss, which have been measured at fair value. The consolidated financial information is presented in Hong Kong dollars ("**HK$**") and all values are rounded to the nearest thousand except when otherwise indicated.

2.2 Changes in accounting policies and disclosures

The Group has adopted the following revised HKFRS Accounting Standards for the first time for the current year's consolidated financial statements.

Amendments to HKAS 21	*Lack of exchangeability*

The above amendment HKFRS Accounting Standards did not have any material impact on the consolidated financial statements.

3 REVENUE AND SEGMENT INFORMATION

Revenue recognised during the years ended 31 March 2026 and 2025 is analysed by the chief operating decision-maker. For the purposes of resource allocation and performance assessment, the executive directors review the overall results and financial position of the Group as a whole prepared based on the same set of material accounting policies. Accordingly, the Group has only one single operating segment and no discrete operating segment financial information is available.

All of the Group's activities (excluding investment in financial assets at fair value through profit or loss) are mainly carried out in Hong Kong and most of the Group's assets and liabilities are mainly located in Hong Kong.

No information about major customers is presented as there is no single customer which individually contributed 10% or more of the total revenue for each of the years ended 31 March 2026 and 2025.

The Group derived revenue from the transfer of goods and services at a point in time in the ordinary course of business. Revenue is recognised in the following major revenue streams:

	Year ended 31 March	
	2026	2025
	HK$'000	*HK$'000*
Revenue from contracts with customers		
Ophthalmic service income	**166,992**	171,044
Sales of prescriptions	**8,234**	7,021
Sales of vision products	**2,594**	2,527
Total	**177,820**	180,592

4 OTHER INCOME AND GAINS/(LOSSES), NET

	Year ended 31 March	
	2026	2025
	HK$'000	*HK$'000*
Other income		
Interest income	**1,490**	4,468
Miscellaneous income	**50**	10
Total other income	**1,540**	4,478
Other gains/(losses), net		
(Loss)/gain on disposal of items of plant and equipment, net	**(12)**	257
Write-off of items of plant and equipment	**–**	(844)
Gain on termination of lease	**567**	–
Loss on reinstatement costs	**–**	(1,617)
Foreign exchange gains/(losses), net	**(37)**	6
Total other gains/(losses), net	**518**	(2,198)
Total other income and gains/(losses), net	**2,058**	2,280

5 EXPENSES BY NATURE

Included in "other expenses" are the expenses related to:

	Year ended 31 March	
	2026	2025
	HK$'000	*HK$'000*
Auditor's remuneration		
– Audit services	**900**	2,800
– Non-audit services	**300**	300
Bank charges	**3,458**	4,018
Business development	**9,607**	7,081
Repair and maintenance	**2,066**	2,600
Professional fees	**28,543**	11,078
Expenses in relation to short-term leases	**855**	439

6 FINANCE COSTS

	Year ended 31 March	
	2026	2025
	HK$'000	*HK$'000*
Interest expenses on lease liabilities	**788**	1,038

7 INCOME TAX

No provision for Hong Kong profits tax has been made as the Group did not generate any assessable profits arising in Hong Kong and Mainland China during the reporting years 31 March 2026 and 2025.

	Year ended 31 March	
	2026	2025
	HK$'000	*HK$'000*
Deferred tax credit	**1,660**	2,623

8 BASIC AND DILUTED LOSS PER SHARE

Basic

The calculation of the basic loss per share is based on the loss for the year attributable to owners of the Company of HK$46,049,000 (2025: HK$34,405,000) and the weighted average number of ordinary shares of 536,334,496 (2025: 528,917,125) in issue.

Diluted

No adjustment has been made to the basic loss per share amount presented for the years ended 31 March 2026 and 2025 as the Group had no potentially dilutive ordinary shares in issue.

9 DIVIDENDS

The board of directors of the Company does not recommend the payment of any dividend in respect of the year ended 31 March 2026 (2025: Nil).

10 TRADE RECEIVABLES

The Group seeks to maintain strict control over its outstanding trade receivable balances. Overdue balances are reviewed regularly by management. The Group does not hold any collateral or other credit enhancements over its trade receivables balances. Trade receivables are non-interest-bearing.

As at 31 March 2026 and 2025, the carrying amount of trade receivables approximated its fair values and is denominated in HK$.

The ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	As at 31 March	
	2026	2025
	HK$'000	*HK$'000*
0-30 days	**3,729**	2,926
31-60 days	**674**	1,115
61-90 days	**430**	707
Over 90 days	**492**	39
Total	**5,325**	4,787

The Group applies the simplified approach permitted by HKFRS 9 to measure expected credit losses which uses a lifetime expected loss allowance for all trade receivables. As at 31 March 2026 and 2025, the Group has assessed that the expected loss allowance for trade receivables was immaterial. Thus no loss allowance provision for trade receivables was recognised during the years ended 31 March 2026 and 2025.

The maximum exposure to credit risk at the reporting date is the carrying value of the trade receivables mentioned above. The Group does not hold any collateral as security.

11 DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES

	As at 31 March	
	2026	2025
	HK$'000	*HK$'000*
Rental and other deposits	**4,249**	5,756
Prepayments	**977**	691
Other receivables *(Notes a & b)*	**2,101**	2,397
	7,327	8,844
Less: Portion classified as non-current assets	**(3,099)**	(3,300)
Portion classified as current assets, gross	**4,228**	5,544
Less: impairment loss on other receivables *(Note c)*	**(1,838)**	(1,838)
Portion classified as current assets	**2,390**	3,706

Notes: Included in "Other receivables" are balances related to:

(a) A loan of HK$14,449,000 was advanced to a medical practitioner. The loan was unsecured, bore interest at 3% per annum, and was originally repayable within 12 months. During the year ended 31 March 2025, the medical practitioner made repayments totalling HK$13,027,000, of which HK$329,000 represented accumulated accrued interests, leaving an outstanding balance of HK$1,750,000 as at 14 January 2025. On the same date, the Group and the medical practitioner executed a deed of assignment under which the medical practitioner assigned to the Group her right to receive an outstanding amount of HK$1,750,000 from Dr. Tse under a guarantee and indemnity agreement entered into between them on 31 August 2022, in full settlement of the remaining loan balance.

(b) An amount of HK$900,000 was due from a medical practitioner. The balance was unsecured, interest-free, and repayable by monthly instalments of HK$100,000. The amount was fully settled during the year ended 31 March 2025.

(c) On 3 November 2025, Dr. Tse was declared bankrupt by the High Court of Hong Kong. Management considers the outstanding receivable assigned to the Group under the deed of assignment to be doubtful and credit-impaired. A full impairment loss of HK$1,750,000 has therefore been recognised in profit or loss during the year ended 31 March 2025. The remaining balance of HK$88,000 represented an advance to Dr. Tse in prior years. A full impairment loss of HK$88,000 has also been recognised in profit or loss during the year ended 31 March 2025.

12 TRADE PAYABLES

The ageing analysis of the trade payables to third parties as at the end of the reporting period based on the invoice date is as follows:

	As at 31 March	
	2026	2025
	HK$'000	*HK$'000*
0-30 days	**3,402**	2,967
31-60 days	**1,834**	2,038
61-90 days	**290**	70
Over 90 days	**1,084**	552
Total	**6,610**	5,627

As at 31 March 2026 and 2025, all trade payables of the Group were denominated in HK$, and their fair value approximated to their carrying amounts.

13. POST BALANCE SHEET EVENT

On 30 May 2025 and 30 June 2025, the Company announced the continued suspension of trading in its shares and the resumption guidance imposed by The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Trading in the Company's shares has been suspended since 15 April 2025.

The announcements also disclosed a series of allegations involving certain Directors and senior management, including alleged (i) misstatements in the Company's IPO prospectus, (ii) undisclosed loan and remuneration arrangements, and (iii) instances of alleged corporate misconduct and governance irregularities.

The Stock Exchange has required the Company to undertake, among other actions, independent forensic investigations, an independent internal control review, and to re-comply with various corporate governance requirements under the Listing Rules. A 18-month remedial period ending on 14 October 2026 has been imposed, during which the Company must satisfy all resumption conditions to avoid potential delisting.

The Directors of the Company are actively working towards fulfilling the resumption guidance with a view to resuming trading in the Company's shares as soon as practicable.

Readers are advised to refer to the Company's announcements dated 30 May 2025 and 30 June 2025 for full details of the allegations, resumption guidance and continuing suspension arrangements.

MANAGEMENT DISCUSSION AND ANALYSIS

The operating environment in FY2026 remained challenging with continued economic headwinds. During the year, the Group also faced internal disruptions related to corporate governance matters, which required significant management attention and resources. With steady progress made in resolving these governance matters and preparing for trading resumption, our core business began to find its footing in the fourth quarter. Through the efforts of the management team, the Group returned to its normal track and focused on steady, long term development.

BUSINESS REVIEW

1. Responding to Allegations, Investigations and Litigation

Entering FY2026, allegations had been made against all of the then Directors, including the Directors then serving as Chief Executive Officer and Co-Chief Executive Officer. The Board established a Special Committee to investigate the corporate governance allegations and a Separate Special Committee to investigate the allegations relating to disclosures in the Company's IPO prospectus. A former Director subsequently made three further rounds of litigations against six other Directors, the last of which was pursued in court by way of an Originating Summons dated 19 September 2025. Responding to these matters demanded sustained management attention throughout the year.

The allegations also resulted in the suspension of trading in the Company's shares from 15 April 2025. In August 2025, a negative publicity campaign arising from the former Director's allegations further damaged the Company's public image.

Addressing the allegations, investigations and litigation, and pursuing the resumption of trading, consumed substantial human and financial resources of the Group.

Taken together, these matters (i) interrupted the growth momentum and the turnaround to positive cash flow that the Group had demonstrated in the second half of FY2025; and (ii) weighed heavily on the Group's business and financial performance. In September 2025, the month immediately following the aforementioned negative publicity campaign, the Group recorded its lowest monthly revenue since listing other than in Chinese New Year months, approximately 11.5% below the same month of the prior year. In addition, third-party legal and professional fees associated with these matters increased to approximately HK$28.0 million of non-recurring costs incurred during the year.

2. Refocusing Operations after Stability Was Restored

During FY2026, the Board and the management team were reconstituted. As the reconstitution progressed, the investigations proceeded on track and the litigation initiated by the former Director moved towards its conclusion, management progressively shifted its focus back to business operations towards the end of FY2026.

The governance and legal matters were substantially resolved around the end of FY2026. As disclosed on 2 April 2026, the Court dismissed the Originating Summons issued by the former Director and all reliefs sought. Later that month, the Special Committee reported that nothing had come to its attention to suggest that any current Directors or senior management had engaged in fraudulent or dishonest acts in relation to the matters investigated.

Meanwhile, signs of recovery emerged. In December 2025, patient visits, new patient bookings and surgical volumes reached or exceeded the levels recorded in the corresponding periods of the previous two years. The recovery continued into the fourth quarter of FY2026: following year-on-year revenue declines of 8.4% and 6.6% in the second and third quarters, respectively, revenue returned to growth in the fourth quarter, increasing by 2.4% year-on-year. In March 2026, the final month of the financial year, revenue increased by approximately 8.3% year-on-year, reaching the highest monthly level in the past two financial years. Against this backdrop, the decline in revenue for the full year narrowed to 1.5%, with revenue of approximately HK$177.8 million, a marked improvement from the 5.4% decline recorded in FY2025.

3. Other Highlights

Notwithstanding these challenges, the Group's business remained resilient and its market leadership intact. The Group remained the highest-volume ICL surgical provider in Hong Kong, finishing calendar year 2025 ranked No. 1 in Hong Kong by ICL surgical volume for the third consecutive year.

The Group also continued to advance its technology leadership. In November 2025, it officially launched the SILK refractive surgery platform under its exclusive partnership with Johnson & Johnson, making it the only provider in Hong Kong offering the comprehensive range of advanced refractive treatments comprising SMILE, SMILE Pro, LASIK, SILK™ and ICL. In March 2026, the Company became one of the first in Hong Kong to introduce Johnson & Johnson's Odyssey™ next-generation premium intraocular lens.

The Group's collaboration with Shenzhen New Frontier United Family Hospital progressed smoothly, with both the patient flow at the ophthalmology centre and the income generated by the centre doubling during FY2026.

Outlook

Looking ahead to FY2027, management believes the Group is well-positioned to build on the recovery momentum established in the fourth quarter of FY2026. The Group has demonstrated its ability to navigate operational disruptions, maintain market leadership, and deliver a return to growth despite a challenging external environment. The management team has remained stable and the business has continued to progress well: for the first five months of FY2027 (April to August 2026), the Group recorded year-on-year revenue growth of over 31% based on management accounts.

The management of the Company has implemented measures to enhance operating efficiency and support revenue recovery, including optimisation of service offerings, promotion of higher-demand treatment types, cost control measures and continued investment in new treatment technologies such as SILK and Alcon's UNITY platform, of which the Group introduced Hong Kong's first units in 2026. Management is confident that it will continue to improve the Group's business performance and deliver further growth, expansion and enhanced returns.

REVENUE OVERVIEWS

We mainly generate revenue from the provision of private ophthalmic services in Hong Kong, including refractive treatments, treatments for other eye problems, consultation and examination services, and sales of prescriptions and vision products. For the year ended 31 March 2026, our revenue amounted to approximately HK$177.8 million, representing a decrease of approximately HK$2.8 million or 1.5% from approximately HK$180.6 million for the year ended 31 March 2025.

The table below sets out the breakdown of revenue by the types of treatments and services and their respective percentage of revenue.

	For the year ended 31 March				
	2026		2025		
	HK$'000	***% of revenue***	*HK$'000*	*% of revenue*	*Change HK$'000*
Refractive Treatment	**87,677**	**49.3%**	103,628	57.4%	(15,951)
Laser refractive surgeries	**37,074**	**20.9%**	48,279	26.7%	(11,205)
Multifocal IOL replacements	**27,259**	**15.3%**	23,987	13.3%	3,272
ICL implantations	**23,344**	**13.1%**	31,362	17.4%	(8,018)
Treatments for other eye problems	**62,870**	**35.4%**	52,715	29.2%	10,155
Standard cataract surgeries	**25,681**	**14.4%**	23,577	13.1%	2,104
Laser procedures	**12,240**	**6.9%**	10,665	5.9%	1,575
PPV surgeries	**13,772**	**7.8%**	9,583	5.3%	4,189
Other treatments/surgeries	**11,177**	**6.3%**	8,890	4.9%	2,287
Consultation and examination services	**16,445**	**9.2%**	14,701	8.1%	1,744
Sales of prescriptions and others	**8,234**	**4.6%**	7,021	3.9%	1,213
Children myopia prevention and control	**2,594**	**1.5%**	2,527	1.4%	67
Revenue	**177,820**	**100.0%**	180,592	100.0%	(2,772)

REFRACTIVE TREATMENTS

Refractive treatments were our largest source of revenue during the year, representing approximately 49.3% of our revenue during FY2026. Refractive treatments include laser refractive surgeries, which include SMILE surgeries, SILK surgeries and LASIK surgeries, multifocal IOL replacement and ICL implantation.

SMILE is a refractive surgery that uses a femtosecond laser to carve a refractive lenticule within the cornea and remove it through a small incision. SMILE also includes its upgraded version, SMILE Pro, which offers a shorter laser treatment time and incorporates CentralLign and OcuLign technologies to assist with centration and cyclotorsion alignment during the procedure. SILK is a laser vision correction procedure that uses the ELITA femtosecond laser to treat myopia and astigmatism by removing a lenticule through a small incision and reshaping the cornea to correct vision. LASIK is a surgery that uses surgical blade and excimer laser to correct myopia, hyperopia and/or astigmatism by modifying the curvature of cornea. As we continue to introduce new laser technologies and equipment, including SILK introduced in FY2026, we have ceased separately disclosing the revenue contribution of each individual type of laser refractive surgery since FY2026. Multifocal IOL replacement is a procedure that corrects cataract and/or other refractive errors by extracting lens from the eye, followed by the replacement of multifocal IOL. ICL implantation is a surgery which places intraocular contact lens in front of the natural lens to correct myopia, hyperopia and astigmatism.

Our revenue generated from refractive treatments decreased by approximately HK$16.0 million, or 15.4%, from approximately HK$103.6 million for FY2025 to approximately HK$87.7 million for FY2026. The decrease in revenue from refractive treatment was mainly due to declines in revenue generated from laser refractive surgeries and ICL implantations of approximately HK$11.2 million and HK$8.0 million, respectively, which was a result of weaker market demand. Such decreases were partially offset by an increase in revenue generated from multifocal IOL replacements of approximately HK$3.3 million during FY2026.

TREATMENTS FOR OTHER EYE PROBLEMS

Treatment for other eye problems include standard cataract surgery, laser procedure, PPV surgeries, and other treatments and surgeries. Revenue generated from these treatments for FY2025 and FY2026 amounted to approximately HK$52.7 million and HK$62.9 million, respectively. This represented approximately 29.2% and 35.4% of our total revenue for the respective years. The revenue from treatment for other eye problems increased by approximately HK$10.2 million or 19.3% in the respective years. The increase was broad-based across the major treatment categories and was mainly attributable to increases in revenue generated from PPV surgeries, other treatments/surgeries, standard cataract surgeries and laser procedures of approximately HK$4.2 million, HK$2.3 million, HK$2.1 million and HK$1.6 million, respectively.

CONSULTATION AND EXAMINATION SERVICES

Consultation and examination services mainly include assessments of eye conditions, such as visual acuity, refraction, anterior segment examination, fundal examination and intraocular pressure measurement. Our revenue generated from consultation and examination services increased by approximately HK$1.7 million or 11.9% from approximately HK$14.7 million for FY2025 to approximately HK$16.4 million for FY2026.

SALES OF PRESCRIPTIONS AND OTHERS

Sales of prescriptions and others are mainly sales of medication prescribed by our medical practitioners to our patients following diagnosis after consultation and examination or treatment services. For FY2025 and FY2026, our revenue generated from sales of prescriptions and others was approximately HK$7.0 million and HK$8.2 million, representing approximately 3.9% and 4.6% of our revenue, respectively.

CHILDREN MYOPIA PREVENTION AND CONTROL

Children's myopia prevention and control aims to manage and slow down myopia progression in children. The services provided include comprehensive eye examinations to assess visual acuity, refractive error and overall eye health. Based on the examination results, personalised consultations are offered to parents and children, including suggestions for managing myopia. Revenue generated from children's myopia prevention and control remained broadly stable at approximately HK$2.6 million for FY2026, compared with approximately HK$2.5 million for FY2025.

OTHER INCOME AND LOSSES, NET

In FY2026, other income, net, mainly consisted of (i) interest income from bank deposits, (ii) disposal gains/(losses) and write-off of plant and equipment, (iii) gains on termination of lease, and (iv) loss on reinstatement costs. Our other income and losses, net for FY2026 decreased by approximately HK$222,000, or 9.7%, compared to FY2025. The decrease was primarily attributable to a decrease in interest income from bank deposits of approximately HK$3.0 million, partially offset by an increase in other gains and losses, net of approximately HK$2.7 million, mainly due to the absence of write-off of items of plant and equipment and loss on reinstatement costs recorded in FY2025, together with a gain on termination of lease recognised in FY2026.

INVENTORIES USED

Inventories used mainly comprised the costs of medical device licences, implantable collamer lenses ("**ICLs**"), intraocular lenses ("**IOLs**"), drugs and dispensary supplies. Our medical device licences are procedure packs, which comprised of medical consumables required for the operation of our medical devices. The procedure packs enable our medical practitioners to perform treatments and surgeries using the respective medical devices. IOLs primarily consist of intraocular lens used in treatments and surgeries. Our drugs and dispensary supplies are drugs prescribed by our medical practitioners to our patients following diagnosis after consultation and supplies are materials used during surgeries. For FY2025 and FY2026, inventories used amounted to approximately HK$38.0 million and HK$35.4 million, respectively, representing approximately 21.0% and 19.9% of our revenue for the corresponding years. The decrease in inventories used as a percentage of revenue was mainly attributable to a change in treatment mix, with a higher contribution from multifocal IOL replacements and standard cataract surgeries during FY2026, which generally have lower inventory cost-to-revenue ratios and contributed to the reduction in overall inventories used as a percentage of revenue.

CONSULTANCY FEES

Consultancy fees represent professional fees paid to our medical practitioners, and consist of fixed fees and/or variable fees being calculated based on the revenue generated by the respective medical practitioners, net of relevant center costs. For FY2025 and FY2026, consultancy fees amounted to approximately HK$64.3 million and HK$62.0 million, representing approximately 35.6% and 34.9% of our total revenue, respectively. The Company adopted a share award plan (the "**Share Award Plan**") on 23 November 2022. On 4 July 2023, the Board resolved to grant 26,088,750 awarded shares to five medical practitioners under the Share Award Plan. Consequently, share-based payments of approximately HK$3.5 million and HK$1.6 million, related to the service providers, were recorded as consultancy fees and recognised in the consolidated statement of comprehensive income in FY2025 and FY2026, respectively.

EMPLOYEE BENEFIT EXPENSES

Our employee benefit expenses include wages, salaries, pension scheme contributions and other related expenses for our staff. For FY2025 and FY2026, our employee benefit expenses amounted to approximately HK$50.2 million and HK$52.5 million, representing approximately 27.8% and 29.5% of our revenue, respectively. On 4 July 2023, the Board resolved to grant 9,367,500 awarded shares to 36 individuals (including two Directors) under the Share Award Plan. As a result, share-based payments of approximately HK$2.7 million and HK$620,000, related to the employees and Directors, were recorded as employee benefit expenses and recognised in the consolidated statement of profit or loss and other comprehensive income for the years ended 31 Mar 2025 and 2026, respectively.

DEPRECIATION OF PLANT AND EQUIPMENT

Depreciation expenses for plant and equipment mainly comprise depreciation expenses on leasehold improvements and medical and office equipment for our medical centres. For FY2025 and FY2026, our depreciation expenses for plant and equipment amounted to approximately HK$10.6 million and HK$9.8 million, representing approximately 5.9% and 5.5% of our revenue, respectively.

DEPRECIATION OF RIGHT-OF-USE ASSETS

Depreciation expenses for right-of-use assets mainly comprise depreciation expenses for leased equipment and properties. For FY2025 and FY2026, our depreciation expenses for right-of-use assets amounted to approximately HK$12.4 million for both financial years, representing approximately 6.9% and 7.0% of our revenue, respectively.

IMPAIRMENT LOSSES ON PLANT AND EQUIPMENT AND RIGHT-OF-USE ASSETS

As at 31 March 2026, the Group's management identified certain medical centers which continued to underperform and estimated the corresponding recoverable amounts of their plant and equipment. Based on these estimates, impairment losses of approximately HK$83,000 (FY2025: 4.4 million) were recognized to write down the carrying amounts of these plant and equipment to their recoverable amounts.

IMPAIRMENT LOSSES ON OTHER RECEIVABLES

A loan of HK$14.4 million was advanced to a medical practitioner. The loan was unsecured, bore interest at 3% per annum, and was originally repayable within 12 months. During the year ended 31 March 2025, the medical practitioner made repayments totalling HK$13.0 million, of which HK$329,000 represented accumulated accrued interests, leaving an outstanding balance of HK$1,750,000 as at 14 January 2025. On the same date, the Group and the medical practitioner executed a deed of assignment under which the medical practitioner assigned to the Group her right to receive an outstanding amount of HK$1.8 million from Dr. Tse under a guarantee and indemnity agreement entered into between them on 31 August 2022, in full settlement of the remaining loan balance. On 3 November 2025, Dr. Tse was declared bankrupt by the High Court of Hong Kong. Management considers the outstanding receivable assigned to the Group under the deed of assignment to be doubtful and credit-impaired. A full impairment loss of HK$1.8 million has therefore been recognised in profit or loss during FY2025. The remaining balance of HK$88,000 represented an advance to Dr. Tse in prior years. A full impairment loss of HK$88,000 has also been recognised in profit or loss during FY2025.

OTHER EXPENSES

Other expenses mainly comprise other general and administration expenses, management fees, business development expenses and bank charges. For FY2025 and FY2026, other expenses were approximately HK$36.9 million and HK$55.0 million, representing approximately 20.5% and 30.9% of our revenue, respectively. The table below sets forth the breakdown of other expenses for FY2025 and FY2026 respectively:

	Year ended 31 March	
	2026	2025
	HK$'000	*HK$'000*
Auditor's remuneration		
– Audit services	**900**	2,800
– Non-audit services	**300**	300
Bank charges	**3,458**	4,018
Business development	**9,607**	7,081
Repair and maintenance	**2,066**	2,600
Professional fees	**28,543**	11,078
Expenses in relation to short-term leases	**855**	439
Other general and administrative expenses	**9,263**	8,622

Bank charges are expenses related to credit card transfers and installment. For FY2025 and FY2026, our bank charges amounted to approximately HK$4.0 million and HK$3.5 million, respectively.

Business development expenses include various activities aimed at promoting eye care and raising awareness of related topics. These activities comprise organising eye care educational talks, producing videos related to eye care, designing websites, organising events for promoting eye care awareness, and printing leaflets. For FY2025 and FY2026, our business development expenses amounted to approximately HK$7.1 million and HK$9.6 million, respectively. The increase in business development expenses in FY2026 was mainly attributable to increased marketing and promotional activities aimed at enhancing patient acquisition and broadening our customer reach.

Professional fees mainly comprise payments to various professional service providers, including legal counsel, consultancy and advisory services. These fees increased by approximately HK$17.5 million, or 157.7%, from approximately HK$11.1 million for FY2025 to HK$28.5 million for FY 2026.

Other general and administrative expenses mainly includes, but not limited to, utilities charges, insurance payments, other telecommunication charges, travelling expenses and entertainment expenses. For FY2025 and FY2026, other general and administrative expenses were relatively stable.

FINANCE COSTS

Finance costs mainly comprise interest expenses on lease liabilities, which was approximately HK$1.0 million and HK$788,000 for FY2025 and FY2026, respectively.

INCOME TAX

The Group recognised taxation for profit at the rate of 16.5% in Hong Kong with reference to the estimated assessable profits during the period.

For FY2025 and FY2026, the Group reported a tax credit of around HK$2.6 million and HK$1.7 million, respectively. The tax credit was calculated at a rate of 16.5% based on a loss before income tax of approximately HK$36.9 million and HK$48.1 million recognized for FY2025 and FY2026, after excluding non-deductible items acknowledged by the Group. The non-deductible expenses mainly represented an impairment loss on plant and equipment, as well as right-of-use assets, totaling approximately HK$83,000 and HK$Nil, respectively.

LOSS FOR THE YEAR

As a result of the foregoing, the Group recorded a loss of approximately HK$46.4 million in FY2026, compared to a loss of approximately HK$34.3 million in FY2025.

CAPITAL EXPENDITURE AND COMMITMENTS

For FY2025 and FY2026, the Group incurred capital expenditures of approximately HK$8.4 million and HK$0.1 million, respectively, primarily due to the purchase of equipment and leasehold improvements for our medical centres.

As at 31 March 2026, the Group does not have capital expenditure contracted for but not yet recognised (2025: Nil).

GEARING RATIO

As at 31 March 2026, the gearing ratio, which is calculated as net debt divided by total capital, is not applicable due to net cash position (2025: not applicable).

CONTINGENT LIABILITIES

The Group had no material contingent liability as at 31 March 2026.

PLEDGE OF ASSETS

The Group had not pledged any assets as at 31 March 2026.

FINANCIAL INSTRUMENTS

Our major financial instruments include financial assets at fair value through profit or loss, trade receivables, financial assets included in deposits, prepayments and other receivables, cash and cash equivalents, lease liabilities, trade payables, financial liabilities included in accruals and other payables. Our management manages such exposure to ensure appropriate measures are implemented on a timely and effective manner.

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT FINANCIAL RISKS

Exposure to Fluctuation in Exchange Rates

Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities which are denominated in a currency that is not our functional currency. We mainly operate in Hong Kong with the majority of the transactions settled in HK$. We closely monitor and manage foreign exchange risk exposures to ensure the exposures do not have significant impact on the operation of the Group. As the Group does not have any significant transactions, assets or liabilities which are settled in currencies other than HK$ during the FY2025 and FY2026, our income and operating cash flows are substantially independent of changes in market foreign exchange rate. We have not used any derivative financial instrument to hedge against our exposure to foreign exchange risk but will closely monitor such risk on an ongoing basis.

Cash Flow and Fair Value Interest Rate Risk

The Group's income and operating cash flows are substantially independent of changes in market interest rates. We do not anticipate significant impact resulted from the reasonable possible change in interest rates.

The Group's fair value interest rate risk mainly arises from lease liabilities at fixed interest rates.

Credit Risk

Our credit risk mainly arises from trade receivables, financial assets included in deposits, prepayments and other receivables, and cash and cash equivalents. Our maximum exposure to credit risk is the carrying amounts of these financial assets.

The credit risk of cash and bank balances are limited because they are deposited in medium or large listed banks. We do not expect that there will be any significant losses from non-performance of these counterparties.

We have assessed that the expected loss rate for trade receivables was immaterial during FY 2026. We have a highly diversified source of patients, without any single patient contributing to revenue in a material way. We also have procedures in place to ensure that follow-up action is taken to recover overdue debts. Our management determines the expected credit losses on trade receivables based on Group's historical observed default rates, existing market conditions as well as forward-looking estimates at the end of the reporting period. Our management reviews patients' billing and payment status at the end of each reporting period to ensure that adequate impairment losses are made for irrecoverable amount. In addition, we have appropriate measures in place to ensure credit sales made to customers with an appropriate credit history. During FY2026, we had not identified specific concentrations of credit risk related to trade receivables, as the amounts recognised mainly represent receivables from credit card companies due to a large number of customers who choose to pay by credit card.

LIQUIDITY RISK

We adopt prudent liquidity risk management by maintaining sufficient cash balances to meet our financial commitments when they become due. Accordingly, we believe that we do not have significant liquidity risk.

CAPITAL RISK MANAGEMENT

Our capital structure consists of shareholders' equity. In order to maintain or adjust our capital structure, we may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets. We monitor capital on the basis of the gearing ratio. The gearing ratio is calculated as net debt divided by total equity. The net debt includes the total borrowings including lease liabilities less cash and cash equivalents. As of 31 March 2025 and 2026, we maintained at net cash position.

EMPLOYEES AND REMUNERATION POLICIES

As at 31 March 2026, the Group employed a total of 109 employees (31 March 2025: 102). The Group ensures that its remuneration packages are comprehensive and competitive from time to time. When determining the emolument payable to the Directors (including the executive Directors), we take into account the experience of the Directors, their level of responsibility and general market conditions. Any discretionary bonus and other merit payments of the Directors are linked to the profit performance of the Group and the individual performance of the Directors. Employees are remunerated with a fixed monthly income plus annual discretionary performance-related bonus.

The Group adopted a share option scheme (the "**Share Option Scheme**") on 26 January 2022 and the Share Award Plan on 23 November 2022. These schemes were established to provide incentives and rewards to eligible participants, including selected employees, for their contributions to the Group and to align the corporate objectives and interests between the Group and its key talents. On 27 June 2023, the Board has resolved to terminate the Share Option Scheme with immediate effect. Details of the Share Award Plan is set out in the Company's Circular dated 7 November 2022. The Group also sponsors selected employees to attend external training courses that suit the needs of the Group's business. We believe that investing in our employees' development and skills not only benefits them personally but also enhances the Group's overall capabilities and competitiveness.

OUTLOOK AND STRATEGIES

Our principal business objective is to achieve sustainable growth, further strengthen our position in the ophthalmic services market and create long-term value for our shareholders by executing the following strategies:

- We will continue to strengthen our market position in Hong Kong by maintaining our market-leading position in SMILE surgery and promoting ICL implantation; while exploring new opportunities for growth and expansion, like exploring tapping into children myopia prevention and control business.

- We plan to acquire equity interests in eye-related clinics, outpatient department or hospitals in the People's Republic of China ("**PRC**") to expand our presence into the PRC under our brand of "Clarity".

- We plan to identify suitable collaboration partners for collaboration and expansion.

- We plan to acquire interests in ophthalmic-related businesses.

LIQUIDITY AND CAPITAL STRUCTURE

During FY2026 our operations were generally financed from internally generated cash flows. The Directors believe that in the long term, our operations will be funded by internally generated cash flows and, if necessary, additional equity financing and bank borrowings. As at 31 March 2026, we had cash and cash equivalents of HK$92.0 million (31 March 2025: HK$132.6 million), all of which were denominated in Hong Kong dollars.

During FY2025 and FY2026, the Group did not use any financial instruments, currency borrowings or other hedging instruments for hedging purposes. The Group has no outstanding bank loans, overdrafts or other borrowings as at 31 March 2026.

Consistent with others in the industry, the Group monitors capital on the basis of the gearing ratio. As at 31 March 2026, the gearing ratio is not applicable due to net cash position (2025: not applicable).

The current ratio (calculated as current assets over current liabilities) was 3.3 times as at 31 March 2026 compared with 4.1 times as at 31 March 2025.

As at 31 March 2026, the Group reported net current assets of HK$70.7 million, as compared with HK$108.6 million as at 31 March 2025.

Net cash used in operating activities of HK$28.4 million during FY2026 as compared to net cash generated from operating activities of HK$17.9 million during FY2025. In FY2026, net cash used in operating activities mainly attributed from loss before income tax of approximately HK$48.1 million, excluding non-cash items of (i) shares-based payments of approximately HK$2.2 million; (ii) depreciation of plant and equipment of approximately HK$9.8 million; and (iii) depreciation of right-of-use assets of approximately HK$12.4 million.

Net cash from investing activities amounted to HK$436,000 in FY2026 as compared to net cash from investing activities of approximately HK$44.4 million in FY2025, which was mainly attributed to maturity of time deposits of approximately HK$50.0 million in FY2025.

Net cash used in financing activities amounted to HK$13.7 million in FY2026, compared to net cash used in financing activities of HK$21.0 million in FY2025, which were all related to lease payments.

SIGNIFICANT INVESTMENTS, ACQUISITION AND DISPOSALS

Except for investments in subsidiaries, there were no significant investments held by the Group as at 31 March 2026.

The Group had no other material acquisitions or disposal of subsidiaries, associates and joint ventures during the reporting period.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 of the Listing Rules as its code of conduct in respect of the securities dealing by the Directors. All current Directors confirmed that they have complied with the Model Code throughout FY2026 and up to the date of this announcement.

DIVIDEND

The Board does not recommend payment of a final dividend in FY2026 (FY2025: Nil). No dividend was paid or declared by the Company or other members of the Group during FY2026.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither our Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities in FY2026 and up to date of this announcement.

MAJOR EVENTS AFTER THE REPORTING PERIOD AND/OR THOSE NOT YET REPORTED IN THE PUBLISHED ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2024 OR THE PUBLISHED INTERIM REPORT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

Suspension of trading in the shares of the Company and Resumption Guidance

(a) Trading in the shares of the Company on the Stock Exchange has been suspended since 15 April 2025 and remains suspended as at the date of this announcement.

(b) The Company received two sets of resumption guidance from the Stock Exchange on 20 May 2025 and 26 June 2025 respectively ("**Resumption Guidance**") for resumption of trading in the shares of the Company on the Stock Exchange. For details of the Resumption Guidance, please refer to the announcements of the Company dated 30 May 2025 and 30 June 2025.

(c) The Special Committee was established on 30 December 2024 to investigate the purported allegations involving certain corporate governance issues. Subsequently, additional allegations were made in respect of other corporate governance issues (collectively, the "**Corporate Governance Allegations**"). The Resumption Guidance stipulates that the completion of an independent forensic investigation into the Corporate Governance Allegations is one of the conditions for the resumption of trading. The Special Committee was reconstituted on 11 November 2025. As disclosed in the Company's announcement of 14 January 2026, FTI Consulting (Hong Kong) was engaged as the independent forensic accountant to the Special Committee to conduct investigation on the Corporate Governance Allegations ("**FTI Investigation**"). For further details, please refer to the announcements of the Company dated 17 January 2025, 20 January 2025, 12 February 2025, 13 May 2025, 14 July 2025, 14 October 2025, 12 November 2025 and 14 January 2026.

(d) Allegations were made against the Company that it made material misstatements in its IPO prospectus and failed to disclose in such prospectus certain re-routing of paid dividends to certain past medical practitioners of the Group for remuneration purposes ("**IPO Allegations**"), as disclosed by the Company on 13 May 2025. The Separate Special Committee was established in May 2025 to investigate the IPO Allegations with an additional member being appointed in June 2025. The Resumption Guidance requires, as a condition for the resumption of trading, an independent forensic investigation into the IPO Allegations. The Separate Special Committee was reconstituted on 11 November 2025, and the additional member appointed in June 2025 resigned with effect from 13 April 2026. As disclosed in the Company's announcement of 5 March 2026, Grant Thornton Advisory Services Limited was appointed as the forensic advisor to the Separate Special Committee to conduct investigation on the IPO Allegations ("**GT Investigation**"). For further details, please refer to the announcements of the Company dated 13 May 2025, 3 July 2025, 14 July 2025, 14 October 2025, 12 November 2025, 14 January 2026, 5 March 2026 and 14 April 2026.

(e) As one of the conditions for the resumption of trading under the Resumption Guidance, an independent internal control review ("**IC Review**") is to be conducted to demonstrate that the Company has in place adequate internal control and procedures to comply with the Listing Rules. For such purpose, the Company appointed one of the Big Four advisory firms ("**IC Adviser**") to conduct IC Review, as disclosed by the Company on 7 April 2026.

Status of FTI Investigation, the GT Investigation and the IC Review

(a) The FTI Investigation was disclosed in the announcements of the Company dated 7 April 2026 and 11 September 2026 respectively, which include, among other things, the background, scope, procedures, key findings and limitations of the FTI Investigation, as well as the opinions of the Special Committee and of the Board on the FTI Investigation.

(b) The GT Investigation was disclosed in the announcement of the Company dated 11 September 2026, which includes, among other things, the background, procedures, limitations and key findings of the GT Investigation, as well as the views of the Separate Special Committee and of the Board on the GT Investigation.

(c) The IC Review was disclosed in the announcement of the Company dated 13 September 2026 which includes, among other things, (a) the background, scope and methodology, limitations, observations and recommendations of the IC Review, (b) the remedial measures taken by the Company, (c) follow-up review conducted by the IC Adviser, including the review on the Company's enhancement measures to address the internal control matters revealed in the FTI Investigation and the GT Investigation, and (d) the views of the Board and the Audit Committee on the IC Review.

Litigations

On 5 February 2025, the Company's indirect wholly-owned subsidiary, Saintford Limited (尚方有限公司), as plaintiff, issued (i) a writ of summons under action number HCA 0198/2025 against WIT Limited, an entity being controlled by Dr. Tse, and (ii) a writ of summons under action number DCCJ 0676/2025 against Dr. Tse. For details of these two legal actions, please refer to the announcement of the Company dated 12 February 2025. Both actions are still active.

A bankruptcy order was made against Dr. Tse by the High Court of Hong Kong under action number HCB 5599/2025 on 3 November 2025, as disclosed in the Company's announcement of 7 November 2025. Following such bankruptcy order, any further proceedings in the DCCJ 0676/2025 action brought by the Company (as creditor) against Dr. Tse (the bankrupt) require leave of the court pursuant to section 12(1) of the Bankruptcy Ordinance (Chapter 6 of the Laws of Hong Kong). Further announcement(s) will be made by the Company as and when appropriate to keep its shareholders and potential investors informed of any material developments concerning the legal actions.

On 22 September 2025, the Company received an originating summons dated 19 September 2025 (the "**OS**") issued at the High Court of Hong Kong by Dr. Tse, as the plaintiff. The OS was issued against the Company under the action number HCMP 1627/2025. A hearing was held on 2 April 2026 and the High Court of Hong Kong pronounced judgment to dismiss the OS including all the reliefs sought by Dr. Tse therein. For further details on the HCMP 1627/2025 action, please refer to the announcements dated 23 September 2025, 27 February 2026 and 2 April 2026, and the circular of the Company dated 5 February 2026.

Change of auditor

Ernst & Young has resigned as the auditor of the Company with effect from 31 March 2026. Crowe was appointed as the new auditor of the Company to fill the casual vacancy and shall hold office until the conclusion of the next annual general meeting of the Company. For further details to the change of auditor, please refer to the announcements of the Company dated 2 April 2026, 14 April 2026 and 11 May 2026.

Non-compliance of Listing Rules

The Company failed to comply with Rules 3.10(1), 3.10A, 3.11 and 3.21 of the Listing Rules, due to insufficient number of independent non-executive Directors and the Company's failure to appoint a replacement within the required period, since the pass away of an independent non-executive Director in February 2024. The Company sought from the Stock Exchange an extension of time to appoint a suitable independent non-executive Director to fill such vacancy. The Company then re-complied with these Rules in May 2024 when it appointed a new independent non-executive Director, as disclosed in the announcements of the Company dated 14 May 2024 and 29 May 2024.

The Company also failed to comply with Rules 3.10, 3.10A, 3.21, 3.25 and 3.27A of the Listing Rules, due to insufficient number of independent non-executive Directors, and its failures to comply with the composition and minimum membership requirements of the audit committee, the remuneration committee and the nomination committee, following the resignation of an independent non-executive Director in November 2024. The Company then re-complied with (i) Rules 3.10, 3.10A, 3.21 partially and 3.27A in June 2025 and (ii) with Rules 3.25 and 3.27A in September 2025, and (iii) fully complied with Rule 3.21 in November 2025, respectively, when it appointed sufficient number of non-executive Directors and independent non-executive Directors to fill the vacancies, as respectively disclosed in the announcements of the Company dated 25 June 2025, 1 September 2025 and 11 November 2025.

USE OF PROCEEDS FROM THE LISTING

The Shares of HK$0.01 each of the Company were listed on the Stock Exchange on 18 February 2022 with 125,000,000 new shares issued at an issue price of HK$1.6 per share. The net proceeds from the initial public offering (the "**IPO**") amounted to approximately HK$181.9 million, after deduction of the underwriting commission and other expenses. The Company applied the proceeds from the Listing in accordance with the proposed applications as set out in the section headed "Future Plans and Use of Proceeds – Use of Proceeds" in the prospectus dated 31 January 2022 (the "**Prospectus**") which is also set out below.

The remaining unutilised net proceeds as at 31 March 2026 were held in bank and it is intended that they will be applied in the manner consistent with the proposed allocations as set out in the Prospectus.

As at 31 March 2026, the Company utilised proceeds from the IPO of approximately HK$91.6 million. The following table sets out the breakdown of the use of proceeds from the IPO:

	Percentage of net proceeds	Estimated net proceeds allocated as disclosed in the Prospectus *(HK$ million)*	Allocated net proceeds from IPO *(HK$ million)*	Net proceeds utilised in FY2023 *(HK$ million)*	Net proceeds utilised in FY2024 *(HK$ million)*	Net proceeds utilised in FY2025 *(HK$ million)*	Net proceeds utilised in FY2026 *(HK$ million)*	Estimated time for utilising the allocated net proceeds	Remaining amount *(HK$million)*
Establishing two new medical centres in Hong Kong for the provision of ophthalmic services	44.8%	110.0	81.5	8.9	43.1	13.0	4.0	By 31 March 2027	12.5
Acquiring majority and/or minority equity interests in one to two eye-related clinics, outpatient department or hospitals in selected cities in the Greater Bay Area	30.5%	75.0	55.5	–	–	–	–	By 31 March 2027	55.5
Setting up an eye-related clinic for the provision of ophthalmic medical services in the PRC with suitable collaboration partners	14.7%	36.0	26.7	–	–	4.4	–	By 31 March 2028	22.3
Working capital	10.00%	24.6	18.2	–	18.2	–	–	N/A	–
TOTAL	**100.0%**	**245.6**	**181.9**	**8.9**	**61.3**	**17.4**	**4.0**		**90.3**

Notes:

(1) The net proceeds from IPO, after deducting the underwriting commission and other expenses of approximately HK$18.1 million, amounted to approximately HK$181.9 million, which is lower than the estimated net proceeds of approximately HK$245.6 million as disclosed in the Prospectus. The difference of approximately HK$63.7 million has been adjusted in the same manner and in the same proportion to the use of proceeds as disclosed in the section headed "Future Plans And Use Of Proceeds" in the Prospectus.

(2) In view of the challenges faced by the Group in its business operations and the uncertainty surrounding the availability of suitable acquisition opportunities in the Greater Bay Area, as well as potential collaboration partners in the PRC, the Board has extended the estimated timeline for utilising the allocated but unutilised net proceeds as at 31 March 2025. As a result, there has been a delay in the estimated timeline for utilising the allocated net proceeds compared to the timeline previously disclosed in the Prospectus.

The Board considers that the extension of the expected timeline for using the unutilised net proceeds will not have any material adverse impact on the existing business and operations of the Group and is in the best interest of the Company and its shareholders as a whole. Save as disclosed in this announcement, there are no other changes to the plan for utilising the proceeds from the IPO as at the date of this announcement.

The expected time for utilising the remaining net proceeds is based on the best estimation of the present and future business market situations made by the Group. It may be subject to further change based on the future development of the market conditions.

CORPORATE GOVERNANCE

The corporate governance principles of the Company emphasise an effective Board, sound internal control, appropriate independence policy, transparency and accountability so as to safeguard the interests of our shareholders. The Board is committed to maintaining high corporate governance standards.

During the year ended 31 March 2026 and up to the date of this announcement, the Company has applied the principles as set forth in the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") which are applicable to the Company.

The Company considers that sufficient measures have been taken to ensure the Company has complied with corporate governance practices as stipulated in the CG Code. The Board will continue to monitor and review the Company's corporate governance practices in order to ensure that such practices meet the general rules and standards as required under the Listing Rules. The Board believes that sound and reasonable corporate governance practices are essential for sustainable growth of the Group and for benefit of the Group and the shareholders as a whole.

In the opinion of the Board, save as disclosed in this announcement, during FY2026 and up to the date of this announcement, the Company has complied with all applicable code provisions as set forth in the CG Code.

Details of the corporate governance practices of the Company will be set out in the Corporate Governance Report contained in the 2026 annual report of the Company.

AUDIT COMMITTEE

The Audit Committee of the Company comprises four independent non-executive Directors, namely, Mr. Wang Can (Chairman of the Audit Committee), Ms. Ci Ying, Dr. Chen Poujian and Mr. Xu Anliang. The Audit Committee has reviewed the accounting principles and practices adopted by the Group, and has also reviewed auditing, internal control and financial reporting matters, including the review of the annual results of the Company in FY2026.

SCOPE OF WORK OF CROWE

The figures in respect of the Group's consolidated statement of profit or loss and other comprehensive income, consolidated statement of financial position and the related notes thereto for FY2026 as set out in this announcement have been agreed by the Group's auditor, Crowe, Certified Public Accountants of Hong Kong, to the amounts set out in the Group's audited consolidated financial statements for FY2026. The work performed by Crowe in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standard on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by Crowe on the preliminary announcement.

By order of the Board
CLARITY MEDICAL GROUP HOLDING LIMITED
JIANG Bo
Executive Director and Chief Executive Officer

Hong Kong, 15 September 2026

As at the date of this announcement, the Board comprises Mr. JIANG Bo as executive Director, Mr. CHEN Jiarong, Professor WANG Qinmei and Mr. SUN Peng as non-executive Directors, Mr. WANG Can, Ms. CI Ying, Dr. CHEN Poujian and Mr. XU Anliang as independent non-executive Directors.